Elanco (ELAN) CFO awarded new deferred stock units in Form 4 filing

(Neutral)

Form Type

Rhea-AI Filing Summary

VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.

Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 8.6337 deferred stock units on Company common stock, valued at $22.82 per unit. After this award, he holds a total of 57.4266 deferred stock units directly. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent and will settle in cash or shares after employment ends or in a specified future year under the Executive Deferral and Stock Match Plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider VanHimbergen Robert M

Role EVP and CFO

Type	Security	Shares	Price	Value
Grant/Award	Deferred Stock Units	8.6337	$22.82	$197.02

Holdings After Transaction: Deferred Stock Units — 57.4266 shares (Direct)

Footnotes (2)

F1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.
F2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

Key Figures

Deferred stock units granted: 8.6337 units Reference price per unit: $22.82 per unit Total deferred stock units held: 57.4266 units +2 more

5 metrics

Deferred stock units granted 8.6337 units Grant to EVP and CFO on April 3, 2026

Reference price per unit $22.82 per unit Value used for deferred stock unit grant

Total deferred stock units held 57.4266 units Direct holdings after the reported transaction

Underlying common stock 8.6337 shares Common stock underlying this specific deferred unit grant

Conversion or exercise price $0.00 Deferred stock units have no exercise price

Key Terms

Deferred Stock Units, Executive Deferral and Stock Match Plan, grant, award, or other acquisition, Common Stock

4 terms

Deferred Stock Units financial

"Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent."

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

Executive Deferral and Stock Match Plan financial

"Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan."

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 04/07/2026 - 05:18 PM

FAQ

What insider transaction did Elanco (ELAN) disclose for EVP and CFO Robert M. VanHimbergen?

Elanco reported that EVP and CFO Robert M. VanHimbergen received a grant of 8.6337 deferred stock units. These units are tied to Elanco common stock and represent a compensation-related award rather than an open-market purchase or sale of shares.

How many deferred stock units does Elanco’s CFO hold after this Form 4 transaction?

Following the reported transaction, Elanco’s CFO holds 57.4266 deferred stock units directly. This total includes the new 8.6337-unit grant and reflects his accumulated balance of cash- or stock-settled rights linked to Elanco common stock under the company’s compensation arrangements.

What does each deferred stock unit represent for Elanco (ELAN) executives?

Each Elanco deferred stock unit represents the right to receive one share of company common stock or the cash equivalent. This structure ties executive compensation to shareholder value without immediately issuing shares or requiring open-market transactions at the time of the award.

When will Elanco’s deferred stock units for the CFO be settled?

Elanco’s deferred stock units for the CFO will settle in cash or shares of company common stock after termination of employment or in a specified future year. Settlement timing follows the terms of the Executive Deferral and Stock Match Plan governing these deferred compensation awards.

Is the Elanco (ELAN) Form 4 transaction an open-market buy or sell of stock?

The Elanco Form 4 reports a grant of deferred stock units, not an open-market buy or sell. The transaction is coded as an acquisition (A) related to compensation, meaning the CFO received units as an award rather than trading existing Elanco shares in the market.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

VanHimbergen Robert M

(Last)

(First)

(Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS

INDIANA

46221

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP and CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Deferred Stock Units	⁽¹⁾	04/03/2026		A		8.6337		⁽²⁾	⁽²⁾	Common Stock	8.6337	$22.82	57.4266	D

Explanation of Responses:

1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.

2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

	/s/ Amy C. Seidel, as Attorney-in-Fact for Robert M. VanHimbergen	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR